Isabel Cobo, Clara Bueno, Antonio Agraz-Doblas, Sara López-Tamargo, Pablo Menendez, Agustín F. Fernández, Raúl F. Pérez, Pauline Schneider, Paolo Petazzi, Meritxell Vinyoles, Paola Ballerini, Francisco Gutierrez-Agüera, Giovanni Cazzaniga, Gustavo F. Bayón, Manuel Ramírez-Orellana, Mario F. Fraga, Ignacio Varela, Pablo Santamarina-Ojeda, Raúl Torres-Ruiz, Michela Bardini, Juan Ramón Tejedor, Ronald W. Stam, Tejedor, J, Bueno, C, Vinyoles, M, Petazzi, P, Agraz-Doblas, A, Cobo, I, Torres-Ruiz, R, Bayon, G, Perez, R, Lopez-Tamargo, S, Gutierrez-Aguera, F, Santamarina-Ojeda, P, Ramirez-Orellana, M, Bardini, M, Cazzaniga, G, Ballerini, P, Schneider, P, Stam, R, Varela, I, Fraga, M, Fernandez, A, Menendez, P, Generalitat de Catalunya, Josep Carreras Leukemia Foundation, Fundación 'la Caixa', European Research Council, European Commission, Ministerio de Economía y Competitividad (España), Ministerio de Ciencia, Innovación y Universidades (España), Agencia Estatal de Investigación (España), Asociación Española Contra el Cáncer, Fundación Unoentrecienmil, Principado de Asturias, Instituto de Salud Carlos III, Fundación General CSIC, Fundación Leo Messi, Obra Social Cajastur, and Liberbank
B cell acute lymphoblastic leukemia (B-ALL) is the most common childhood cancer. As predicted by its prenatal origin, infant B-ALL (iB-ALL) shows an exceptionally silent DNA mutational landscape, suggesting that alternative epigenetic mechanisms may substantially contribute to its leukemogenesis. Here, we have integrated genome-wide DNA methylome and transcriptome data from 69 patients with de novo MLL-rearranged leukemia (MLLr) and non-MLLr iB-ALL leukemia uniformly treated according to the Interfant-99/06 protocol. iB-ALL methylome signatures display a plethora of common and specific alterations associated with chromatin states related to enhancer and transcriptional control in normal hematopoietic cells. DNA methylation, gene expression, and gene coexpression network analyses segregated MLLr away from non-MLLr iB-ALL and identified a coordinated and enriched expression of the AP-1 complex members FOS and JUN and RUNX factors in MLLr iB-ALL, consistent with the significant enrichment of hypomethylated CpGs in these genes. Integrative methylome-transcriptome analysis identified consistent cancer cell vulnerabilities, revealed a robust iB-ALL–specific gene expression–correlating dmCpG signature, and confirmed an epigenetic control of AP-1 and RUNX members in reshaping the molecular network of MLLr iB-ALL. Finally, pharmacological inhibition or functional ablation of AP-1 dramatically impaired MLLr-leukemic growth in vitro and in vivo using MLLr-iB-ALL patient–derived xenografts, providing rationale for new therapeutic avenues in MLLr-iB-ALL., We thank CERCA/Generalitat de Catalunya (SGR180) and Fundació Josep Carreras-Obra Social la Caixa for their institutional support. Financial support for this work was obtained from the European Research Council (CoG-2014-646903 and PoC-2018-811220 to PM), the Spanish Ministry of Economy and Competitiveness (SAF-2019-108160-R and SAF2016-76758-R to PM and IV, respectively), the Spanish Association against cancer (AECC-CI-2015 and PROYE18061FERN to CB and MFF), the Fundación Uno entre Cienmil (to PM), the Health Institute Carlos III (ISCIII/FEDER, PI17/01028, PI15/00892, PI18/01527 to CB and AFF/MFF, respectively). We also acknowledge the Plan de Ciencia, Tecnología e Innovación from the Asturias Government cofunding 2018–2022/FEDER (IDI/2018/146to MFF). MFF also acknowledges funding from Fundación General CSIC (0348_CIE_6_E). PM also acknowledges financial support from Fundación Leo Messi. JRT and MV are supported by Juan de la Cierva fellowships by the Spanish Ministry of Science and Innovation (FJCI-2015-26965, IJC2018-36825-I, IJCI-2017-3317) and IUOPA-ISPA-FINBA (The IUOPA is supported by the Obra Social Cajastur-Liberbank, Spain). RTR is supported by a fellowship from the AECC scientific foundation. RFP and PSO are supported by the Severo Ochoa program (BP17-114 and BP17-165, respectively).